Sunita Babbar joined Retinagenix in July 2019 as the Vice President of Toxicology and Nonclinical Development with 20 years of experience in small and large molecule nonclinical and clinical drug development. She has an extensive background in toxicology, pharmacology, and DMPK studies in support of nonclinical development and clinical trials to meet US and EU regulatory requirements from discovery to registration and in authoring regulatory submissions, including BLAs, NDAs, MAAs, sNDAs, and INDs. Most recently, she served as the VP of Nonclinical development at Parvus Inc. Previously, she was Senior Director, Nonclinical Development at Revance Therapeutics where she led nonclinical development of dermal and injectable Botulinum toxin products to support BLA filings for aesthetic and therapeutic indications. Prior to that, she was Director of Toxicology at NeurogesX Inc. and played a key role in the writing and filing of the NDA and MAA for a dermal patch (Qutenza®) for neuropathic pain leading to its successful approval in the US and the EU. Sunita is a Diplomate of the American Board of Toxicology (DABT). She earned a Bachelor of Pharmacy degree from Indian Institute of Technology, Varanasi, India, and received her M.S. in Pharmacology from School of Pharmacy, Idaho State University. Currently she is completing her Doctorate degree in Regulatory Science from the School of Pharmacy, University of Southern California, Los Angeles.